Patients with type 2 diabetes mellitus (T2DM) are at greater risk of developing cardiovascular disease (CVD) . We aimed to explore the association between several baseline parameters and risk of cardiovascular (CV) events in patients with T2DM and whether evidence from clinical data at T2DM onset could be useful in identifying patients at risk of subsequent CV events. Data for baseline visits were extracted from 34 globally conducted clinical studies. Framingham risk equation was used to assess the CV risk at baseline. In the overall pooled population (n=18,076) , 2130 (13.6%) patients had CVD history at baseline. The mean (SD) age of the patients was 56.8 (10.7) years, total cholesterol was 196.4 (41.0) mg/dL, low-density lipoprotein (LDL) was 115.4 (36.8) mg/dL, systolic blood pressure (SBP) was 132.7 (14.6) mmHg with disease duration of 5. (5.10) years and Framingham risk score (FRS) of 20.71 (12.68) . An incremental risk for subsequent CV events was observed in patients having none or multiple risk factors. Patients having CVD history and FRS ≥20% were significantly associated with a higher risk of CV events (HR [95% CI]: 7.8 [5.0, 12.3]; p<0.001; Figure) . Overall, these analyses suggests that clinical data collected at the onset and follow-up of T2DM such as CVD history, high LDL and SBP may help in identifying patients who are at high risk of subsequent CV events.
A.Malhotra:Employee; Novartis India . G.Bader:Employee; Novartis AG.
Novartis Pharma AG